Predicting the possibility of a return of skin cancer with only one blood test

According to RCO News AgencyIn this experiment, the researchers can detect tissues from the DNA tumor to diagnose the “Melanoma” tumor by a simple blood sample. These tissues may not be seen with CT scans.

Although the test is not complete, it can help identify patients who need urgent treatment because of the possibility of their cancer return.

The melanoma tumor is a metastasis or comprehensive tumor of the most deadly types of skin cancer.

“We predict that this test will be used to monitor patients with skin cancer at different times and early diagnosis of melanoma disease,” said Dr. David Polsky, a senior author of the New York University.

He added: “If blood tests contain a tissue from a tumor DNA, the doctor may use more advanced imaging technologies to search for small, diagnostic tumors or move on to a more severe treatment.”

Melanoma cancer is related to the skin’s cellular cell. It accounts for only one percent of skin cancers, but it accounts for the highest deaths from skin cancer, as it can quickly infect other organs. Early diagnosis of the disease is one of the best ways to increase the likelihood of survival.

Pulseki and his colleagues focused on Step 2 Melanoma. At this point, the cancer tumor contaminates the adjacent lymph nodes, where immune cells are made and stored.

Doctors undergo surgery to remove more cancer tumors before starting the medication to eliminate the remaining tumor cells. Patients then become CT scans to examine any symptoms of return, but some patients have small remnants of the tumor that are very small for observing CT scans.

Pulseki and his team turned to a Tumor Tumor, called CTDNA, to early recognition. These tissues are released throughout the natural life cycle of tumor cells and circulate in blood plasma. Researchers can identify them by obvious mutations that are specific to cancer cells.

As part of a clinical trial, the research team examined the blood samples of the newly underwent surgery. Participants who started treating medication or receiving placebo were also taken over the blood test samples within 6 months, 6 months, 6 months and 6 months.

Immediately after surgery, 5 % of patients in their blood plasma were “CTDNA” tissue.

Scientists found that each of these patients had the experience of returning cancer. Also, when the tissue increased during their blood tests or stays high during the test, the melanoma was more likely to return.

The tissue of “CTDNA” predicted the return of cancer in 5 % of the time, but the absence of this tissue did not mean that patients were completely released from the disease.

A negative response in 5 % of the time was to predict the person’s cancer return. However, some patients saw the disease return without diagnosing this tissue.

“These experiments are very accurate when they are positive, but they are not as accurate when they are negative,” Paul said.

The next step is to make the results of this experiment available to a clinical molecular pathology lab. There is a decision on its use in treatment. A clinical trial can indicate whether the use of blood tests results in better results.

“The clinical application of this experiment will be a major progress for the management of patients with melanoma, especially for patients whose disease has spread beyond the skin,” said Pulseki.

This study is published in The Lancet Oncology.

The end of the message